Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 7 days matching "ALS"

ResearchRSSYesterday

Alzheimer’s gene variant may influence toxic protein spread in ALS

Scientists discovered that people with ALS who carry a specific gene variant called APOE4 (known to increase Alzheimer's risk) are more likely to have toxic protein clumps spread to more areas of their brain. This suggests the same gene may affect how disease progresses differently in ALS patients. The finding could help doctors better understand why ALS affects people differently.

WHY IT MATTERSIf you have ALS and carry the APOE4 variant, this research suggests you may experience different patterns of disease progression, which could eventually help doctors predict outcomes and tailor treatment approaches for individual patients.
💬 Ask your doctoramyotrophic lateral sclerosis
ResearchRSS3 days ago

Cholesterol-lowering statins don’t affect ALS progression: Study

A new study found that statin drugs, which lower cholesterol, do not slow down ALS or change how long people with ALS live. This means doctors should prescribe statins to ALS patients based on their cholesterol levels, not because of their ALS diagnosis.

WHY IT MATTERSIf you have ALS and high cholesterol, you can now feel confident that taking statins for your heart health won't interfere with your ALS treatment or make your disease worse.
💬 Ask your doctorAmyotrophic Lateral Sclerosis (ALS)
ResearchRSS4 days ago

Inflammation may explain why ALS progression is faster for some

Scientists found that some people with ALS get worse faster than others because of differences in how their immune cells cause inflammation. The study shows that the amount of inflammation in the spinal cord isn't the main factor — instead, it's the type of immune activity that matters. This discovery could lead to new treatments that slow down ALS by targeting specific inflammatory markers.

WHY IT MATTERSIf doctors can identify which inflammatory markers predict faster progression, they may be able to personalize treatment plans and potentially slow disease advancement for individual ALS patients.
💬 Ask your doctoramyotrophic lateral sclerosis

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases